Astellas Pharma Australia has announced that Xtandi (enzalutamide) will be listed on the Pharmaceutical Benefits Scheme from 1st December 2014 for the treatment of men with castration-resistant metastatic prostate cancer (mCRPC), whose disease has progressed on or after docetaxel therapy. This marks an important step in the management of metastatic prostate cancer as enzalutamide is the latest in a new generation of treatments which can extend survival and improve the quality of life for men with mCRPC.

Xtandi (enzalutamide) is an oral, once-daily androgen receptor signalling inhibitor that works differently from other treatments for patients with mCRPC. It works at three distinct steps in the androgen receptor (AR) signalling pathway within the cancer cells, and has been shown to decrease cancer cell growth and can cause cancer cell death.3 In vitro data does not necessarily predict human clinical effect.

For more details, go to: http://www.firstwordpharma.com/node/1247438?tsid=28&region_id=3#axzz3JgPWBqsK